FDA Compliance
510(k) Premarket Notification
The Most Common FDA Pathway
Applies to: Class II device manufacturers entering the US market
What Is 510(k) Premarket Notification and Why It Matters?
The 510(k) Premarket Notification is the most common FDA pathway for bringing a medical device to the U.S. market. It requires manufacturers to demonstrate that their device is substantially equivalent to a legally marketed predicate device. Rather than proving safety and effectiveness from scratch, the 510(k) process allows you to reference an existing device and show that your product performs in a comparable way. While this is considered the more streamlined FDA route, the submission still demands thorough technical documentation, rigorous data, and precise regulatory language.
How Can We Help?
At Certilance, we guide you through every stage of your 510(k) submission with clarity and precision. From selecting the right predicate device and defining your intended use, to preparing the full submission package, our consultants ensure your file meets FDA expectations from day one. We help you avoid the most common pitfalls to keep your timeline on track and your path to market as efficient as possible.
FAQ
510(k) — frequently asked questions
Yes. Medical devices must obtain FDA clearance or approval before being marketed in the United States. The pathway depends on device classification, intended use, and risk profile.
The U.S. Food and Drug Administration (FDA) regulates devices through:
- 510(k) premarket notification
- De Novo classification
- Premarket Approval (PMA)
Each pathway has different evidence, testing, and review requirements.
No. CE marking and FDA approval are completely separate regulatory systems. Compliance with one does not grant access to the other market.
FDA does not formally certify ISO standards. However, an ISO 13485-aligned quality system strongly supports FDA Quality System Regulation (QSR) compliance and significantly reduces inspection findings.
Certilance helps manufacturers prepare documentation, quality systems, and regulatory evidence aligned with FDA expectations, ensuring submissions and inspections proceed efficiently.
FDA timelines vary by pathway (510(k), De Novo, or PMA) and submission quality. While FDA review periods are defined, real-world timelines are often extended due to deficiency letters, additional data requests, or design control gaps.
Early regulatory alignment significantly reduces delays.
FDA-related costs depend on:
- Regulatory pathway
- Testing and validation requirements
- Submission complexity
- FDA user fees (where applicable)
Well-structured submissions reduce review cycles and overall cost exposure.
FDA Compliance
Related services
510(k)
Ready to start your 510(k) project?
Book a free consultation and we will map the gaps, the timeline and the cost before any work begins.